🔗 Share this article

While America proceeds with sweeping adjustments to its vaccination recommendations, one figure appears somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by casting doubt on COVID-19 shots during the pandemic and has focused upon potential deaths after Covid vaccination in her brief tenure at the FDA.

Planned Shifts to Pediatric Vaccine Schedule

Agency leaders had intended to unveil sweeping revisions to the pediatric vaccine schedule in December, synchronizing the US with the Danish vaccine program, sources say – a significant shift that would place the US at odds with a large portion of the global community with insufficient data for public health gain. This reveal has been postponed until the coming year.

In place of Vinay Prasad, Dr. Høeg is set to present at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing some pediatric vaccine recommendations in the US in order to be more like the Danish model, a country with nationalized medicine and a population about the size of the state of Wisconsin.

So far statements, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Background

Dr. Høeg has no obvious track record in drug development, approval processes or management, which has been standard for former directors of the CBER. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She has not conducted a scientific study. She is not versed in leading a major agency. She is not an expert in drug approvals.”

Previous directors of the center would “grasp legal statutes and the science of medication creation”, noted Janet Woodcock. “Objectively, she doesn’t have the type of experience that previous people who led CBER have had.”

This division has an vast portfolio at the FDA, Woodcock stated.

“The public just focuses on the innovative therapies, but the generic program approves numerous generic medications. There is also a biosimilars program, OTC medication office and so forth, and each of these have to be supervised,” Woodcock said. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a major administrative component to the role, which manages more than 5,000 employees. “It is a enormous leadership role, if you perform it correctly,” she added.

Response and Disputed Initiatives

When asked about inquiries about Dr. Høeg's qualifications and whether this assignment indicates increased cooperation among FDA leaders on immunizations, a press secretary stated that the “concerns rely on incorrect assumptions”.

“Her resume matches the responsibilities of her job,” the official said, pointing to the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s new expedited review system, a controversial rapid therapy clearance system that reportedly worried her former heads. “By what process are these medications being chosen for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There is a lot of confidentiality happening at the FDA right now.”

In general, he remarked, “the agency appears to be shifting towards laxer oversight of all drugs, with the exception of immunizations.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if problematic, history, some experts observe. She released a analysis using unverified volunteer-provided data to assess the incidence of myocarditis after Covid immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are riskier than they are.

Among her “desired changes” for the incoming administration featured altering rules for novel immunizations and halting “unnecessary” vaccines, she remarked post-election on a audio program. At the agency, Dr. Høeg has reportedly floated the idea of preventing teenage boys from getting Covid vaccinations.

“She’s an all-around true believer who begins with her preconceived notions and works backwards to fit the evidence in a very deceptive, fraudulent manner,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Høeg joined fellow contrarians, {like|